Publications by authors named "B Hidvegi"
Background: Novel therapies for cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) demonstrated efficacy and safety in previous trials. However, data on the comparison of these treatments is still lacking, limiting their integration into clinical practice. Therefore, our aim is to perform a systematic review and network meta-analysis to compare the efficacy and safety of novel systemic therapies in CLE.
View Article and Find Full Text PDFArticle Synopsis
- Calcinosis cutis is the buildup of calcium salts in the skin that can lead to inflammation and joint issues, mostly seen in autoimmune connective tissue diseases (CTDs), but its prevalence is not well understood.
- * A retrospective study analyzed 839 CTD patients, finding that 56 had calcinosis, which is about 6.67%, with an average diagnosis age of 41 years and an onset time of almost 6 years.
- * The study suggests calcinosis, while rare in the general population, is a significant issue for CTD patients; more research is needed on its causes and treatment options.
(1) Background: Calcinosis of the skin mainly appears in connective tissue disorders (dystrophic subtype). It may cause inflammation, ulceration, pain, and restricted joint mobility. Management is difficult; sodium thiosulfate is one potential therapeutic agent with promising data on intralesional and topical formulation for smaller calcified lesions.
View Article and Find Full Text PDFArticle Synopsis
- Amyloid deposits are linked to various chronic diseases, with Primary Localized Cutaneous Amyloidosis (PLCA) being a dermatological condition characterized by amyloid buildup in the skin.
- The study analyzed 41 PLCA patients in Central Europe, revealing a higher prevalence in females and specific age and location patterns of the disease.
- Most patients responded best to topical corticosteroids, but the study highlights the need for more research and standardized treatment guidelines due to the condition's rarity.
Cutaneous lupus erythematosus (CLE) is an autoimmune skin disease with various clinical forms, including the subtypes of discoid lupus erythematosus (DLE) and subacute cutaneous lupus erythematosus (SCLE). The altered function of the programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) axis in CLE pathogenesis has been suggested. Here, the soluble forms of PD-1 (sPD-1) and PD-L1 (sPD-L1) were explored in untreated DLE and SCLE.
View Article and Find Full Text PDF